Ascendis Pharma A/S’s (ASND) Outperform Rating Reaffirmed at Royal Bank Of Canada

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a report issued on Friday, Benzinga reports. They presently have a $290.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada‘s target price would indicate a potential upside of 6.88% from the stock’s previous close.

ASND has been the subject of several other reports. Morgan Stanley reduced their price target on Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating for the company in a report on Tuesday, September 1st. BMO Capital Markets reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Barclays dropped their price objective on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Citigroup dropped their price objective on Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a report on Monday, October 26th. Finally, Bank of America cut their price objective on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Nineteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $307.10.

Ascendis Pharma A/S Stock Up 1.6%

ASND traded up $4.25 during trading on Friday, reaching $271.32. 28,649 shares of the stock traded hands, compared to its average volume of 699,983. The stock’s 50-day simple moving average is $242.58 and its two-hundred day simple moving average is $239.65. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. Ascendis Pharma A/S has a fifty-two week low of $188.08 and a fifty-two week high of $282.15. The stock has a market cap of $16.93 billion, a price-to-earnings ratio of 20.94 and a beta of 0.40.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The firm had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. As a group, equities research analysts expect that Ascendis Pharma A/S will post 3.43 EPS for the current year.

Insider Transactions at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 40.00% of the company’s stock.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC raised its holdings in Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after buying an additional 450,000 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Ascendis Pharma A/S by 24.8% during the 1st quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock worth $80,318,000 after acquiring an additional 69,673 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Ascendis Pharma A/S by 27.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 227,013 shares of the biotechnology company’s stock worth $51,602,000 after acquiring an additional 48,275 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its stake in shares of Ascendis Pharma A/S by 68.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock worth $60,053,000 after acquiring an additional 91,822 shares in the last quarter. Finally, Orbimed Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 5.8% during the 1st quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company’s stock worth $41,624,000 after acquiring an additional 10,000 shares in the last quarter.

Ascendis Pharma A/S News Roundup

These are some of the ASND news items that stood out recently:

• Positive Sentiment: Regulatory progress could support future growth. European regulators recommended marketing authorization for TransCon CNP; Ascendis expects a European Commission decision in Q4 2026 and plans a first launch in Germany in Q1 2027. Q3 results and pipeline update
• Neutral Sentiment: Employee warrant grants. Ascendis granted 28,030 warrants to employees. The grants may support retention but could modestly dilute existing shareholders. Employee warrant announcement
• Negative Sentiment: One target was lowered. HC Wainwright cut its target from $344 to $335, though it maintained a buy rating. HC Wainwright ratings

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.